Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab

R. L. Johnston, J. Lutzky, A. Chodhry, Jamie S Barkin

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Anti-CTLA-4 antibodies are human monoclonal antibodies previously studied in the treatment of metastatic melanoma (MM). CTLA-4 is an inhibitory receptor on cytotoxic T cells, blockade of which will activate T cells allowing them to attack malignant cells. Normal host cells may also be affected, and immune-mediated enterocolitis can occur. This is a prospective observational study on the use of corticosteroids and infliximab in the treatment of patients with immune-mediated colitis secondary to anti-CTLA-4 antibody treatment of MM. Five patients presented with colitis after medication administration. Patients were treated with high-dose corticosteroids for 1 week, but diarrhea did not completely abate in any of them. They were then treated successfully with infliximab. One patient had recurrence of symptoms and responded to repeat treatment with infliximab. Patients who develop immune-mediated colitis after administration of anti-CTLA-4 antibodies have previously been reported to respond to corticosteroids, but in our study, all required treatment with infliximab.

Original languageEnglish
Pages (from-to)2538-2540
Number of pages3
JournalDigestive Diseases and Sciences
Volume54
Issue number11
DOIs
StatePublished - Nov 1 2009

Fingerprint

CTLA-4 Antigen
Colitis
Antibodies
Adrenal Cortex Hormones
Melanoma
T-Lymphocytes
Enterocolitis
Therapeutics
Observational Studies
Diarrhea
Monoclonal Antibodies
Infliximab
Prospective Studies
Recurrence

Keywords

  • Antibodies
  • Colitis
  • Drug therapy
  • Immunology
  • Infliximab
  • T-Lymphocytes
  • Tremelimumab

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. / Johnston, R. L.; Lutzky, J.; Chodhry, A.; Barkin, Jamie S.

In: Digestive Diseases and Sciences, Vol. 54, No. 11, 01.11.2009, p. 2538-2540.

Research output: Contribution to journalArticle

@article{065015ce04c04ca7aee38a6e8386d958,
title = "Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab",
abstract = "Anti-CTLA-4 antibodies are human monoclonal antibodies previously studied in the treatment of metastatic melanoma (MM). CTLA-4 is an inhibitory receptor on cytotoxic T cells, blockade of which will activate T cells allowing them to attack malignant cells. Normal host cells may also be affected, and immune-mediated enterocolitis can occur. This is a prospective observational study on the use of corticosteroids and infliximab in the treatment of patients with immune-mediated colitis secondary to anti-CTLA-4 antibody treatment of MM. Five patients presented with colitis after medication administration. Patients were treated with high-dose corticosteroids for 1 week, but diarrhea did not completely abate in any of them. They were then treated successfully with infliximab. One patient had recurrence of symptoms and responded to repeat treatment with infliximab. Patients who develop immune-mediated colitis after administration of anti-CTLA-4 antibodies have previously been reported to respond to corticosteroids, but in our study, all required treatment with infliximab.",
keywords = "Antibodies, Colitis, Drug therapy, Immunology, Infliximab, T-Lymphocytes, Tremelimumab",
author = "Johnston, {R. L.} and J. Lutzky and A. Chodhry and Barkin, {Jamie S}",
year = "2009",
month = "11",
day = "1",
doi = "10.1007/s10620-008-0641-z",
language = "English",
volume = "54",
pages = "2538--2540",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "11",

}

TY - JOUR

T1 - Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab

AU - Johnston, R. L.

AU - Lutzky, J.

AU - Chodhry, A.

AU - Barkin, Jamie S

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Anti-CTLA-4 antibodies are human monoclonal antibodies previously studied in the treatment of metastatic melanoma (MM). CTLA-4 is an inhibitory receptor on cytotoxic T cells, blockade of which will activate T cells allowing them to attack malignant cells. Normal host cells may also be affected, and immune-mediated enterocolitis can occur. This is a prospective observational study on the use of corticosteroids and infliximab in the treatment of patients with immune-mediated colitis secondary to anti-CTLA-4 antibody treatment of MM. Five patients presented with colitis after medication administration. Patients were treated with high-dose corticosteroids for 1 week, but diarrhea did not completely abate in any of them. They were then treated successfully with infliximab. One patient had recurrence of symptoms and responded to repeat treatment with infliximab. Patients who develop immune-mediated colitis after administration of anti-CTLA-4 antibodies have previously been reported to respond to corticosteroids, but in our study, all required treatment with infliximab.

AB - Anti-CTLA-4 antibodies are human monoclonal antibodies previously studied in the treatment of metastatic melanoma (MM). CTLA-4 is an inhibitory receptor on cytotoxic T cells, blockade of which will activate T cells allowing them to attack malignant cells. Normal host cells may also be affected, and immune-mediated enterocolitis can occur. This is a prospective observational study on the use of corticosteroids and infliximab in the treatment of patients with immune-mediated colitis secondary to anti-CTLA-4 antibody treatment of MM. Five patients presented with colitis after medication administration. Patients were treated with high-dose corticosteroids for 1 week, but diarrhea did not completely abate in any of them. They were then treated successfully with infliximab. One patient had recurrence of symptoms and responded to repeat treatment with infliximab. Patients who develop immune-mediated colitis after administration of anti-CTLA-4 antibodies have previously been reported to respond to corticosteroids, but in our study, all required treatment with infliximab.

KW - Antibodies

KW - Colitis

KW - Drug therapy

KW - Immunology

KW - Infliximab

KW - T-Lymphocytes

KW - Tremelimumab

UR - http://www.scopus.com/inward/record.url?scp=70350244517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350244517&partnerID=8YFLogxK

U2 - 10.1007/s10620-008-0641-z

DO - 10.1007/s10620-008-0641-z

M3 - Article

VL - 54

SP - 2538

EP - 2540

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 11

ER -